Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW01-200 in Advanced Tumors
NCT07629258Phase 1Recruiting
- Sponsor
- Groovy Medicine
- Start
- Jul 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of GW01-200 in solid tumor and hematological malignancies (4 arms), sponsored by Groovy Medicine. Primary endpoints: Number of participants with adverse events (AEs) and serious AEs (SAEs), Recommended dose(s) for expansion (RDEs) and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
GW01-200
03
Conditions
solid tumorhematological malignancies
Beyond the preview
Go deeper on NCT07629258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629258.